Reuters - Eli Lilly and Co on Thursday
forecast 2008 earnings above Wall Street expectations and said
it remained on track to seek U.S. approval this month for
prasugrel, a blood clot preventer, which posted mixed results
in a recent large clinical trial.
Thursday, December 6, 2007
Subscribe to:
Posts (Atom)
